▼ -28.11% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Genesis Healthcare in the last 3 months. The average price target is $0.57, with a high forecast of $0.57 and a low forecast of $0.57. The average price target represents a -28.11% upside from the last price of $0.79.
The current consensus among 1 investment analysts is to sell stock in Genesis Healthcare. This rating has held steady since November 2019, when it changed from a Hold consensus rating.
Genesis Healthcare, Inc., together with its subsidiaries, owns and operates skilled nursing facilities and assisted/senior living facilities in the United States. The company operates through three segments: Inpatient Services; Rehabilitation Therapy Services; and Other Services. It also provides a range of rehabilitation therapy services, including speech-language pathology, physical therapy, occupational therapy, and respiratory therapy. In addition, the company offers other specialty medical services, such as physician, staffing, and other healthcare related services. As of April 23, 2020, it provided inpatient services through a network of approximately 400 skilled nursing facilities and assisted/senior living communities in 25 states; and supplied rehabilitation and respiratory therapy to approximately 1,200 healthcare locations in 44 states, the District of Columbia and China. The company was formerly known as FC-GEN Operations Investment, LLC and changed its name to Genesis HealthCare, Inc. in February 2015. Genesis HealthCare, Inc. was founded in 2003 and is headquartered in Kennett Square, Pennsylvania.